Chronic blepharitis due to Demodex: A prospective study in Sfax (Tunisia)

##plugins.themes.academic_pro.article.sidebar##

Published Feb 18, 2024
https://doi.org/10.62438/tunismed.v102i2.4449
Download
pdf
Vol. 102 No. 2 (2024): Tunis med feb 2024

##plugins.themes.academic_pro.article.main##

Mohamed Slim Werda
Parasitology and Mycology Laboratory, Habib Bourguiba Hospital, Sfax, Tunisia
Fatma Cheikhrouhou
Parasitology and Mycology Laboratory, Habib Bourguiba Hospital, Sfax, Tunisia
Zeineb Ben Zina
Parasitology and Mycology Laboratory, Habib Bourguiba Hospital, Sfax, Tunisia
Fattouma Makni
Parasitology and Mycology Laboratory, Habib Bourguiba Hospital, Sfax, Tunisia
Ali Ayadi
Parasitology and Mycology Laboratory, Habib Bourguiba Hospital, Sfax, Tunisia

Abstract

Introduction: Chronic blepharitis is a common cause of eye irritation and dryness. They are often treated without regard to causal factors such as parasites which are rarely mentioned. Aim: To describe the role of Demodex in the pathogenesis of chronic blepharitis, to analyze the epidemiological, clinical, diagnostic and therapeutic particularities. Methods: This is a prospective, case-control study conducted in the mycology parasitology department at the Habib Bourguiba university hospital in Sfax covering 100 cases with chronic blepharitis and 87 control cases.Clinical examination and eyelash removal were performed with direct examination for qualitative and quantitative analysis, before and after treatment.  Results: Demodex was significantly more found in patients than in controls (48% vs 13.8%). The quantitative analysis showed a significant difference between the two groups with 52.1% of Demodex (+++) for patients versus 8.3% for controls.Demodex blepharitis were treated with yellow oxid mercure ophthalmic ointment with a good outcome in 81,3%. Conclusion: Although it is admitted to be a saprophyte of the skin, a large number of arguments argues for the incrimination of Demodex in the etiopathogenesis of chronic blepharitis, hence the interest of eyelashes examination and a parasitic research in front of any chronic blepharitis resistant to usual treatments. In case of positive research, a specific treatment should be prescribed. Its effectiveness is another argument for the etiological diagnosis.

Keywords:

chronic blepharitis, demodex folliculorum, demodex brevis, Tunisia

##plugins.themes.academic_pro.article.details##

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

References

  1. Cheikhrouhou F, Makni F, Neji S, Sellami H, Masmoudi A, Turki H, et al. La démodécidose humaine dans la région de Sfax (Tunisie). Bull Société Pathol Exot. 1 oct 2010;103(4):238‑42.
  2. Türk M, Oztürk I, Sener AG, Küçükbay S, Afşar I, Maden A. Comparison of incidence of Demodex folliculorum on the eyelash follicule in normal people and blepharitis patients. Turk Parazitolojii Derg. 2007;31(4):296‑7.
  3. Kabataş N, Doğan AŞ, Kabataş EU, Acar M, Biçer T, Gürdal C. The Effect of Demodex Infestation on Blepharitis and the Ocular Symptoms. Eye Contact Lens. janv 2017;43(1):64‑7.
  4. Czepita D, Kuźna-Grygiel W, Czepita M, Grobelny A. Demodex folliculorum and Demodex brevis as a cause of chronic marginal blepharitis. Ann Acad Med Stetin. 2007;53(1):63‑67.
  5. Huismans H. Demodex folliculorum. Klin Monatsbl Augenheilkd. sept 1988;193(3):304‑6.
  6. Forton F, Germaux MA, Brasseur T, De Liever A, Laporte M, Mathys C, et al. Demodicosis and rosacea: epidemiology and significance in daily dermatologic practice. J Am Acad Dermatol. janv 2005;52(1):74‑87.
  7. Forton F, Seys B. Density of Demodex folliculorum in rosacea: a case-control study using standardized skin-surface biopsy. Br J Dermatol. juin 1993;128(6):650‑9.
  8. Basta-Juzbasić A, Subić JS, Ljubojević S. Demodex folliculorum in development of dermatitis rosaceiformis steroidica and rosacea-related diseases. Clin Dermatol. avr 2002;20(2):135‑40.
  9. Moravvej H, Dehghan-Mangabadi M, Abbasian MR, Meshkat-Razavi G. Association of rosacea with demodicosis. Arch Iran Med. avr 2007;10(2):199‑203.
  10. Erbağci Z, Ozgöztaşi O. The significance of Demodex folliculorum density in rosacea. Int J Dermatol. juin 1998;37(6):421‑5.
  11. Rufli T, Büchner SA. T-cell subsets in acne rosacea lesions and the possible role of Demodex folliculorum. Dermatologica. 1984;169(1):1‑5.
  12. Forton F. Demodex and perifollicular inflammation in man: review and report of 69 biopsies. Ann Dermatol Venereol. 1986;113(11):1047‑58.
  13. Lacey N, Delaney S, Kavanagh K, Powell FC. Mite-related bacterial antigens stimulate inflammatory cells in rosacea. Br J Dermatol. sept 2007;157(3):474‑81.
  14. Bhandari V, Reddy JK. Blepharitis: always remember Demodex. Middle East Afr J Ophthalmol. 2014;21(4):317‑20.
  15. Zhu Y. Investigation of demodactic blepharitis ciliaris in Huainan areas. Chin J Pest Control 2002;18(6):302–303.
  16. Tian Y, Li C. Investigation on infection of human Demodex in blepharons of patients with blepharitis. Chin J Parasitic Dis Contr 2004;17:236–237
  17. Kemal M, Sümer Z, Toker MI, Erdoğan H, Topalkara A, Akbulut M. The Prevalence of Demodex folliculorum in blepharitis patients and the normal population. Ophthalmic Epidemiol. août 2005;12(4):287‑90.
  18. Zhao YE, Wu LP, Hu L, Xu JR. Association of blepharitis with Demodex: a meta-analysis. Ophthalmic Epidemiol. avr 2012;19(2):95‑102.
  19. Galvis-Ramírez V, Tello-Hernández A, Álvarez-Osorio L, Rey-Serrano JJ. [The prevalence of Demodex folliculorum infection in patients attending a general ophthalmological consultation]. Rev Salud Publica Bogota Colomb. déc 2011;13(6):990‑7.
  20. Demmler M, de Kaspar HM, Möhring C, Klauss V. Blepharitis. Demodex folliculorum, associated pathogen spectrum and specific therapy. Ophthalmol Z Dtsch Ophthalmol Ges. mars 1997;94(3):191‑6.
  21. Gamboa-Barragán JÁ. Incidencia de Demodex folliculorum en blefaritis. Rev Mex Oftalmol. 2003;77(2):44‑7.
  22. Prasher DP. Demodex Blepharitis: Indian Scenario. http://www.aiosedu.org/uploads/BOB7
  23. Grice EA, Segre JA. The skin microbiome. Nat Rev Microbiol. avr 2011;9(4):244‑53.
  24. Wesolowska M, Knysz B, Reich A, Blazejewska D, Czarnecki M, Gladysz A, et al. Prevalence of Demodex spp. in eyelash follicles in different populations. Arch Med Sci AMS. 12 mai 2014;10(2):319‑24.
  25. Elston CA, Elston DM. Demodex mites. Clin Dermatol. 2014;32(6):739‑43.
  26. Uyttebroeck W, Nijs I, Maudgal PC, Missotten L. Incidence of Demodex folliculorum on the eyelash follicle in normal people and in blepharitis patients. Bull Soc Belge Ophtalmol. 1982;201:83‑7.
  27. Dhingra KK, Saroha V, Gupta P, Khurana N. Demodex-associated dermatologic conditions--A coincidence or an etiological correlate. Review with a report of a rare case of sebaceous adenoma. Pathol Res Pract. 2009;205(6):423‑6.
  28. Baima B, Sticherling M. Demodicidosis revisited. Acta Derm Venereol. 2002;82(1):3‑6.
  29. Anane S, Mokni M, Beltaief O. Démodécie rosacéiforme et blépharite chronique. Ann Dermatol Vénéréologie. 2011;138(1):30‑4.
  30. Pena GP, Andrade Filho JS. Is demodex really non-pathogenic? Rev Inst Med Trop Sao Paulo. 2000;42(3):171‑3.
  31. Ayres S, Ayres S. Demodectic eruptions (demodicidosis) in the human. 30 years’ experience with 2 commonly unrecognized entities: pityriasis folliculorum (Demodex) and acne rosacea (Demodex type). Arch Dermatol. mai 1961;83:816‑27.
  32. Hasegawa T. A case report of the management of demodicosis in the golden hamster. J Vet Med Sci. avr 1995;57(2):337‑8.
  33. Hoekzema R, Hulsebosch HJ, Bos JD. Demodicidosis or rosacea: what did we treat? Br J Dermatol. août 1995;133(2):294‑9.
  34. Persi A, Rebora A. Metronidazole and Demodex folliculorum. Acta Derm Venereol. 1981;61(2):182‑3.
  35. Arrúa M, Samudio M, Fariña N, Cibils D, Laspina F, Sanabria R, et al. Comparative study of the efficacy of different treatment options in patients with chronic blepharitis. Arch Soc Espanola Oftalmol. mars 2015;90(3):112‑8.
  36. Baima B, Sticherling M. Demodicidosis revisited. Acta Derm Venereol. 2002;82(1):3‑6.
  37. Holzchuh FG, Hida RY, Moscovici BK, Villa Albers MB, Santo RM, Kara-José N, et al. Clinical treatment of ocular Demodex folliculorum by systemic ivermectin. Am J Ophthalmol. juin 2011;151(6):1030-1034.e1.
  38. Kamoun B, Fourati M, Feki J, Mlik M, Karray F, Trigui A, et al. Blepharitis due to Demodex: myth or reality?. J Fr Ophtalmol. mai 1999;22(5):525‑7.
  39. Rodríguez AE, Ferrer C, Alió JL. Chronic blepharitis and Demodex. Arch Soc Espanola Oftalmol. nov 2005;80(11):635‑42.
  40. Thygeson P. Etiology and treatment of blepharitis; a study in military personnel. Arch Ophthalmol Chic Ill 1929. oct 1946;36(4):445‑77.
  41. Martinaud C, Gaillard T, Pons S, Fournier B, Brisou P. Blépharite chronique : quel rôle pour Demodex folliculorum ? À propos d’un cas. Ann Biol Clin (Paris). 1 nov 2009;67(6):701‑4.
  42. Rivera N, Molina P, Torres A. Measurement of the index of infection by Demodex spp in patients with chronic blepharitis and in patients without other ocular diseases. Rev Chil Infectologia Organo Of Soc Chil Infectologia. oct 2013;30(5):494‑501.
  43. Yam JCS, Tang BSF, Chan TM, Cheng ACK. Ocular demodicidosis as a risk factor of adult recurrent chalazion. Eur J Ophthalmol. 2014;24(2):159‑63.
  44. Pisella PJ, Baudouin C, Hoang-Xuan T. Surface oculaire: rapport 2015 [présenté à la] Société française d’ophtalmologie. Issy-les-Moulineaux: Elsevier Masson; 2015.
  45. Tighe S, Gao YY, Tseng SCG. Terpinen-4-ol is the Most Active Ingredient of Tea Tree Oil to Kill Demodex Mites. Transl Vis Sci Technol. 13 nov 2013;2(7):2.